# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week buprenorphine check, seen the same day by addiction medicine. **S**

## History of present illness

Ms. Holiday returns one week after starting buprenorphine with naloxone and is seen by Dr. Ortiz of addiction medicine on the same day. She took half a film on the first day and one film daily since, under the tongue each morning, without missing a dose. She has used no heroin or other opioids. She had no withdrawal, but cravings come back each evening, most of all after a show. She has had mild constipation and no drowsiness. She picked up two naloxone two-packs; her friend came with her and was shown how to use them. She is still drinking four or five drinks on performance nights. She read her results from last week by phone. She says she came back because nobody lectured her at the first visit. **S**

| Element | Detail |
|---|---|
| Buprenorphine | 8 mg daily for six days, every dose taken |
| Opioid use | None |
| Cravings | Every evening, strongest after shows |
| Side effects | Mild constipation |
| Naloxone | Two two-packs dispensed; her friend trained |
| Alcohol | Four or five drinks on performance nights |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No sweats, chills, or drowsiness |
| Gastrointestinal | Positive | Mild constipation; no nausea, vomiting, or abdominal pain |
| Psychiatric | Positive | Evening cravings; mood low at times; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 68.2 kg; BMI 25.1 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert and engaged; blood pressure 122/78, pulse 78 |
| Eyes | Pupils normal in size; no yawning, tearing, or gooseflesh |
| Psychiatric | Calm; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder on buprenorphine** (F11.20). No opioid use, but cravings persist at 8 mg. Urine test today shows buprenorphine and its metabolite and no fentanyl or other opioids. Dr. Ortiz agrees with increasing the dose. Safety reviewed: no thoughts of suicide or self-harm; naloxone in place. **S**
   - Increase buprenorphine with naloxone to 16 mg (two films) once daily.
   - Fiber, fluids, and a stool softener as needed for constipation.
   - Weekly counseling and a peer recovery coach, as she chose today.
2. **Alcohol use disorder** (F10.20). Drinking unchanged. Naltrexone cannot be used with buprenorphine; kidney function is normal (creatinine 0.72 mg/dL), so acamprosate is suitable. **S**
   - Start acamprosate 666 mg three times daily.
   - Continue thiamine.
   - PEth and liver tests at the next visit.
3. **Screening results**. Hepatitis C antibody nonreactive (signal-to-cutoff 0.09); hepatitis B surface antigen and core antibody nonreactive, and surface antibody 3 mIU/mL, so she is not immune; HIV antigen-antibody test nonreactive. AST 52 and GGT 84 U/L with ALT 38, consistent with alcohol; albumin 4.0 g/dL and bilirubin 0.7 mg/dL normal; FIB-4 1.18, below 1.3, which makes advanced fibrosis unlikely. **S**
   - Second hepatitis B vaccine dose at the next visit.
   - Repeat liver tests with PEth.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | 8 mg daily, every dose taken; evening cravings; no withdrawal or sedation; increased to 16 mg |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Completed today | Seen one week after starting |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine and norbuprenorphine present; no fentanyl or other opioids |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | No other controlled-substance prescriptions |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | Two two-packs dispensed; her friend trained |
| Self-management | Overdose prevention: never using alone and fentanyl test strips | Every visit | Completed today | Reviewed; fentanyl test strips given |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | She chose weekly counseling and a peer recovery coach |
| Self-management | Oral care on sublingual buprenorphine | At the start and yearly | Completed today | After the film dissolves, swish water and swallow, and wait an hour before brushing; dental visit advised |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Up to date | PEth 312 ng/mL and AUDIT-C 8 a week ago; four or five drinks on performance nights |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Creatinine 0.72 mg/dL and eGFR 113 a week ago; acamprosate started |
| Medication safety | Naltrexone for alcohol use disorder | First-line for alcohol use disorder unless opioids are needed | Not indicated | Contraindicated with buprenorphine |
| Examination | Alcohol withdrawal risk | Every visit | Completed today | No history of withdrawal seizures or delirium; no withdrawal symptoms |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine 100 mg daily |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Up to date | AST 52, ALT 38, GGT 84 U/L a week ago; albumin and bilirubin normal |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Up to date | 1.18 a week ago (age 33, AST 52, ALT 38, platelets 236): low risk |
| Imaging | Vibration-controlled transient elastography | If FIB-4 is 1.3 or higher | Not indicated | FIB-4 below 1.3 |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care, then yearly while any drug use continues | Up to date | All nonreactive a week ago |
| Self-management | Hepatitis A and B vaccines | Hepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apart | Up to date | First doses a week ago; hepatitis B dose 2 next visit |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Up to date | PHQ-9 9 a week ago; next at the five-week visit |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; overdose risk lowered by buprenorphine and naloxone; the 988 Suicide & Crisis Lifeline saved in her phone |
| Laboratory | Pregnancy test and contraception | Before starting buprenorphine; contraception discussed | Up to date | Urine pregnancy test negative a week ago |
| Referral | Addiction medicine consultation | At the start of treatment | Completed today | Seen by Dr. Ortiz today |

## Goal progress

- Stay on buprenorphine without interruption through six months, including through any return to use. In progress; target 1948-10-19. **S**
- Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit. Outcome by 1948-04-27: Two naloxone two-packs dispensed; her friend trained. **S**
- Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months. In progress; target 1948-10-19. **S**
- Hepatitis A and B vaccine series completed by six months. In progress; target 1948-10-19. **S**
- PHQ-9 score below 5 by six months. In progress; target 1948-10-19. **S**

## Medication changes

- Stopped: Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily **S**
- Started: Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily **S**
- Started: Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily **S**

## Guideline basis

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026), Substance Abuse and Mental Health Services Administration
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Visit in two weeks; she leaves on tour in five days and will call in, with the in-person visit when she returns. Counselor weekly. Results by phone. **S**
- Next scheduled visit 1948-05-26: five-week recovery review and second hepatitis B vaccine. **S**
